1. Home
  2. PLAB vs NTLA Comparison

PLAB vs NTLA Comparison

Compare PLAB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Photronics Inc.

PLAB

Photronics Inc.

HOLD

Current Price

$48.07

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.44

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLAB
NTLA
Founded
1969
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.6B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
PLAB
NTLA
Price
$48.07
$13.44
Analyst Decision
Strong Buy
Buy
Analyst Count
3
21
Target Price
$44.33
$20.23
AVG Volume (30 Days)
803.7K
3.9M
Earning Date
05-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
9.09
27.43
EPS
0.74
N/A
Revenue
$535,276,000.00
$67,671,000.00
Revenue This Year
$6.70
N/A
Revenue Next Year
$4.96
$62.75
P/E Ratio
$69.43
N/A
Revenue Growth
18.77
16.92
52 Week Low
$16.59
$6.83
52 Week High
$52.79
$28.24

Technical Indicators

Market Signals
Indicator
PLAB
NTLA
Relative Strength Index (RSI) 59.48 46.16
Support Level $21.30 $11.93
Resistance Level N/A $14.32
Average True Range (ATR) 2.05 1.11
MACD 0.17 -0.16
Stochastic Oscillator 49.74 22.25

Price Performance

Historical Comparison
PLAB
NTLA

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: